Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2599666 in Healthy Subjects and Alzheimer's Disease
NCT02614131Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2015
- Primary completion
- Dec 2016
- Modality
- Antibody Fragments, PEGylated Peptides
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of LY2599666 in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by Eli Lilly and Company. Started Dec 2015; status: terminated.
02
Drugs
LY2599666
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT02614131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02614131.